

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claims 1-14. (Canceled)

- Claim 15. (Original) A photosensitizing treatment method for treating malignant lesions of the skin in a human patient comprising (a) administering an agent which is not a photosensitizer but induces the synthesis of protoporphyrin IX in vivo and then (b) exposing the lesions of the skin to a wavelength of light within the photoactivating spectrum of protoporphyrin IX.
- Claim 16. (Original) The method of claim 15, wherein said agent induces synthesis of protoporphyrin IX in the heme biosynthetic pathway.
- Claim 17. (Original) The method of claim 15, wherein said agent is a precursor of protoporphyrin IX.
- Claim 18. (Original) The method of claim 15, wherein said wavelength of light is 350-640 nm.
- Claim 19. (Original) The method of claim 15, wherein said wavelength of light is 600-700 nm.
- Claim 20. (Original) The method of claim 15, wherein said agent is 5-amino levulinic acid.
- Claim 21. (Original) The method of claim 15, wherein said agent is administered topically.
- Claim 22. (Original) The method of claim 15, wherein said agent is administered systemically.
- Claim 23. (Original) The method of claim 15, wherein said light is generated from an artificial light source.
- Claim 24. (Original) The method of claim 15, wherein said light is only within the absorption spectrum of protoporphyrin IX.

Claim 25. (Original) The method of claim 15, wherein said photoactivating light is limited to the red and blue regions of the spectrum.